WHY BENLYSTA?

Dr. Elaine Lambert, Rheumatologist

Paid consultant to GSK at the time of filming.

  • TRANSCRIPT

    DR. LAMBERT: I’m Elaine Lambert, I’m a private practice Rheumatologist in San Mateo, California.

    ON-SCREEN TEXT: Dr. Elaine Lambert Rheumatologist
    Paid consultant to GSK at the time of filming

    ON-SCREEN TEXT: “Why BENLYSTA”

    DR. LAMBERT: Contributing factors that made my decision very easy to start BENLYSTA were the fact that we had been waiting for so very long for a new agent to come along to treat our patients with lupus,...

    ON-SCREEN TEXT: Waiting so long for new agent

    DR. LAMBERT: ... and so in 2011 it had been more than 50 years since we had a new drug approved by the FDA. The previous drugs that were grandfathered in were, a glucocorticoid, an antimalarial, and aspirin, and we’d been borrowing immunosuppressive drugs from many different other areas to treat our patients and mostly having to rely on them, and also high doses of glucocorticoids.

    DR. LAMBERT: So, to have BENLYSTA come along as a drug that was specifically designed for lupus and it was in a double-blinded, placebo-controlled clinical trial setting that we’d never had data for lupus in the past. So, that made it very easy to say to patients, “I want you to try this new agent.”

    ON-SCREEN TEXT: “Specifically designed for lupus”

    DR. LAMBERT: And also, the safety profile made me very comfortable to start people on BENLYSTA to help control their lupus.

    ON-SCREEN TEXT: Comfortable with safety profile

    DR. LAMBERT: Click on the link for more information

    ON-SCREEN TEXT: Visit the website

    ON-SCREEN TEXT: BENLYSTA is indicated for patients aged ≥5 with active, autoantibody-positive systemic lupus erythematosus (SLE) receiving standard therapy and patients aged ≥18 with active lupus nephritis receiving standard therapy. BENLYSTA is not recommended in patients with severe active central nervous system lupus or in combination with other biologics.

    IMPORTANT SAFETY INFORMATION

    CONTRAINDICATION

    Previous anaphylaxis with BENLYSTA.

    Serious Infections: Serious and sometimes fatal infections have been reported, and occurred more frequently with BENLYSTA. Use caution in patients with severe or chronic infections, and consider interrupting therapy in patients with a new infection.

    Progressive Multifocal Leukoencephalopathy (PML): Cases of JC virus-associated PML resulting in neurological deficits, including fatal cases, have been reported. If PML is confirmed, consider stopping immunosuppressant therapy, including BENLYSTA.

    Please see additional Important Safety Information and full Prescribing Information, including Medication Guide, on the BENLYSTAHCP.com website.

    ON-SCREEN TEXT:

    BENLYSTA
    (belimumab)
    Intravenous Use 120 mg/vial
    Subcutaneous Use 200 mg/mL

    GSK Logo

    Trademarks are owned by or licensed to the GSK group of companies. |
    ©2022 GSK or licensor. BELVID220053 March 2022. Produced in USA.

You may also like

WHY BENLYSTA?

Dr. William Pendergraft, Nephrologist

BENLYSTA PATIENT CASE

Dr. Don Thomas, Rheumatologist

JOIN US FOR
A LIVE WEBINAR

Paid consultants to GSK at the time of filming.